Back to News​
Press Release

Alamar Biosciences Expands Executive Leadership to Power Next Phase of Growth

Back to Publications​
  • October 15, 2025

Tod White Promoted to President; Justin McAnear Appointed Chief Financial Officer

Fremont, CA – October 15, 2025.  Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced key additions to its executive leadership team. These appointments reflect the company’s continued momentum and its commitment to scaling innovation, operational excellence, and strategic growth.

The board has promoted Tod White, JD, to the role of President. Since joining Alamar, Tod has played a central role in shaping the company’s trajectory—leading across finance, HR, investor relations, fundraising, corporate development, and legal. His promotion recognizes not only his broad impact but also the trust and confidence the board places in his ability to help guide Alamar through its next chapter.

“Tod has been a cornerstone of our leadership team,” said Yuling Luo, Founder, Chairman and CEO of Alamar Biosciences. “His ability to navigate complexity and drive cross-functional alignment has been instrumental to our success. This elevation reflects the board’s belief in Tod’s vision and leadership as we scale our operations and deepen our impact.”

To further strengthen its financial leadership, Alamar welcomes Justin McAnear as Chief Financial Officer. Justin brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Justin served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition.  Justin also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.

“Justin’s arrival marks an exciting moment for Alamar,” said Luo. “He brings a rare combination of strategic insight, operational discipline, and a deep understanding of scaling complex organizations. I look forward to partnering with him as we continue to grow and evolve the company.”

Together, White and McAnear bring complementary strengths that will help Alamar navigate the opportunities ahead. Their combined expertise reinforces the company’s commitment to innovation, integrity, and industry-leading performance.

Linkedin

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Linkedin

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition.  He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.